Thanks! You've successfully subscribed to the BONEZONE®/OMTEC® Monthly eNewsletter!

Please take a moment to tell us more about yourself and help us keep unwanted emails out of your inbox.

Choose one or more mailing lists:
BONEZONE/OMTEC Monthly eNewsletter
OMTEC Conference Updates
Advertising/Sponsorship Opportunities
Exhibiting Opportunities
* Indicates a required field.

Company Financials: Orthopaedics and Spine

ORTHOWORLD’s estimates place 3Q12 market growth at 3% over 3Q11, as shown in Exhibit 1 on the following page. Performance highlights follow and pertain to 3Q unless otherwise noted.

Exhibit 1: Orthopaedic Sales1 Increases by Product Segment: 3Q12 vs. 3Q11

For Financials_OK3Q12UpdateSE_JV-800 

Notes to Exhibit 1:

1. Orthopaedic products; constant currency, pro forma growth
2. Includes biologics
3. For the quarter ended 8/31/12; includes Dental. Spine includes Bone Stim and Biologics; Bone Stim reflects all Bone Healing sales. Excludes trauma acquisition.
4. Excludes Synthes acquisition.
5. Spine
6. For the quarter ended 9/30/12
7. Extremities: extremities + fixation combined; Endoscopy: endoscopic + communications, most of which is orthopaedic; Spine: neuro + spine. Total growth excludes Patient Handling.
8. ORTHOWORLD estimates

 

Alphatec

$47.8MM, flat (U.S. $31.0MM, -5%; ex-U.S. $16.8MM, +12%)

  • Launched BridgePoint spinous process fixation system, NEXoss biologic
  • Phygen asset acquisition brings access to >100 U.S. spine surgeons, Leucadia AutoLok Pedicle Screw

ArthroCare

$57.0MM, +5% (Americas $37.1MM, +9%; International $19.9MM, -3%)

Ÿ Sports Medicine $55.2MM, +8%; Other (includes spine) $1.8MM, -23%

  • Minimal sales arising from agreement to supply Wright Medical with Opus knotless suture technology
  • Launched phase 2 marketing strategy: medical education campaign to reinforce clinical facts concerning Coblation during knee arthroscopy; phase 3 to focus on ACL reconstruction; phase 4 is platform to deliver Coblation in versatile operating modes (expected late 2013)

Biomet (FY 1Q13 ended 8/31/12)

$707.4MM, +10% (U.S. $452.2MM, +9%; Europe $142.9MM, +9%; International $112.3MM, +14%)

Reconstructive $393.0MM, +2% (U.S. +1%)

  • Ÿ Hips +2%; Knees +2%; Bone Cement/Other +4%

Sports Med/Extremities/Trauma (S.E.T.) $127.3MM, +59% (U.S. +52%)

  • Ÿ Sports Med +12%; Extremities +15%; Trauma +199%

Spine & Bone Healing $77.9MM, +5% (U.S. +5)

  • Ÿ Spine +11%; Bone Healing -9%

S.E.T. includes acquisition. Excluding trauma acquisition +10% (U.S. +11%)
Trauma excluding acquisition, flat worldwide and U.S.

Hips/Knees

  • Commenced rollout of Taperloc Complete microplasty version to strong response
  • Further decline in Oxford Partial Knee sales
  • Initiated U.S. lifetime warranty for Oxford Partial implanted with Signature, as well as direct-to-consumer advertising
  • Launched Signature dynamic femoral positioning

S.E.T.

  • Launched Comprehensive Nano Stemless Shoulder in Europe; will launch Comprehensive SRS Shoulder there in FY3Q

4 COMMENTS

Security code
Refresh